Promedior is a clinical-stage biotechnology company leading one of the most exciting new frontiers of antifibrotic drug development, the direct therapeutic regulation of the fundamental cellular populations controlling aberrant immune system responses in fibrosis. By specifically targeting the monocytes and monocyte-derived cells precisely at the sites of injury, the source of the initiation and progression of fibrosis, Promedior’s first-in-class therapeutics are designed to treat and resolve fibrosis across a variety of severe diseases and injuries. Rapidly advancing drug candidates through multiple human clinical trials and building a deep pipeline, Promedior is developing therapeutics for a wide variety of serious fibrotic diseases of the lung, kidney and eye, such as pulmonary fibrosis, scleroderma and COPD; acute and chronic nephropathy; and glaucoma, age-related macular degeneration, macular edema and diabetic retinopathy.
Proprietary platform: Promedior is the first and only company dedicated to creating pentraxin therapeutics based on the precise and targeted regulation of monocytes and monocyte-derived cells, which are fundamentally important drivers of the immune system’s cellular response to all forms of disease and injury. Recent discoveries by Promedior and others have shown that monocytes, a type of white blood cell, are the source and master controller of profibrotic and pro-inflammatory fibrocyte and macrophage cell populations as well as pro-resolution cytokines, such as interleukin-10. Expanding on the groundbreaking discoveries of Promedior and its collaborators, the company is creating a therapeutic platform based on pentraxins, a family of naturally-occurring proteins known to regulate a number of important immune, inflammatory, and fibrotic processes in the body.
Scientific leadership: Promedior’s staff, founders and scientific collaborators are experts in fibrotic disease research, and have made many of the recent breakthrough discoveries relating to how pentraxin proteins control the monocyte-driven processes that lead to the aggressive initiation and progression of fibrosis and organ failure across a broad array of tissue settings.
Strategic focus: Promedior has built a strong team of experienced drug development professionals and collaborators, raised approximately $41 million from blue chip venture investors, successfully advanced lead therapeutic candidates to and through human clinical trials, and developed and secured important intellectual property relating to the pioneering discovery and application of pentraxin therapeutics.